礼来再现强劲业绩,并再次上调了全年业绩指引,而明星GLP-1药物替尔泊肽有望成为2025年全球医药行业“销冠”。 10月30日,美国礼来公司(LLY.US)发布2025年三季报。第三季度营收达到176亿美元,同比增长54%,超出行业预期;净利润达到55.83亿美元,而去年同期为9.7亿美元;每股收益6.21美元,按非公认会计准则(Non-GAAP)计算经调整每股收益7.02美元。 与第二季度...
Source Link礼来再现强劲业绩,并再次上调了全年业绩指引,而明星GLP-1药物替尔泊肽有望成为2025年全球医药行业“销冠”。 10月30日,美国礼来公司(LLY.US)发布2025年三季报。第三季度营收达到176亿美元,同比增长54%,超出行业预期;净利润达到55.83亿美元,而去年同期为9.7亿美元;每股收益6.21美元,按非公认会计准则(Non-GAAP)计算经调整每股收益7.02美元。 与第二季度...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.